Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel
Authors:
- 10 February 2019
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 37 (5) , 403-410
Abstract
Purpose: Several studies have reported that among patients with localized prostate cancer, black men have a shorter overall survival (OS) time than white men, but few data exist for men with advanced prostate cancer. The primary goal of this analysis was to compare the OS in black and white men with metastatic castration-resistant prostate cancer (mCRPC) who were treated in phase III clinical trials with docetaxel plus prednisone (DP) or a DP-containing regimen. Methods: Individual participant data from 8,820 men with mCRPC randomly assigned in nine phase III trials to DP or a DP-containing regimen were combined. Race was based on self-report. The primary end point was OS. The Cox proportional hazards regression model was used to assess the prognostic importance of race (black v white) adjusted for established risk factors common across the trials (age, prostate-specific antigen, performance status, alkaline phosphatase, hemoglobin, and sites of metastases). Results: Of 8,820 men, 7,528 (85%) were white, 500 (6%) were black, 424 (5%) were Asian, and 368 (4%) were of unknown race. Black men were younger and had worse performance status, higher testosterone and prostate-specific antigen, and lower hemoglobin than white men. Despite these differences, the median OS was 21.0 months (95% CI, 19.4 to 22.5 months) versus 21.2 months (95% CI, 20.8 to 21.7 months) in black and white men, respectively. The pooled multivariable hazard ratio of 0.81 (95% CI, 0.72 to 0.91) demonstrates that overall, black men have a statistically significant decreased risk of death compared with white men ( P < .001). Conclusion: When adjusted for known prognostic factors, we observed a statistically significant increased OS in black versus white men with mCRPC who were enrolled in these clinical trials. The mechanism for these differences is not known.Keywords
This publication has 40 references indexed in Scilit:
- Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401Journal of Clinical Oncology, 2012
- Identification of Docetaxel Resistance Genes in Castration-Resistant Prostate CancerMolecular Cancer Therapeutics, 2012
- Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancerThe Prostate, 2010
- Racial/ethnic disparities in survival among men diagnosed with prostate cancer in TexasCancer, 2010
- Clinical Outcomes by Age in Men With Hormone Refractory Prostate Cancer: A Pooled Analysis of 8 Cancer and Leukemia Group B (CALGB) StudiesJournal of Urology, 2006
- Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate CancerNew England Journal of Medicine, 2004
- Explaining racial differences in prostate cancer in the United States: Sociology or biology?The Prostate, 2004
- Black Race is an Adverse Prognostic Factor for Prostate Cancer Recurrence Following Radical Prostatectomy in an Equal Access Health Care SettingJournal of Urology, 1996
- A general parametric approach to the meta‐analysis of randomized clinical trialsStatistics in Medicine, 1991
- Meta-analysis in clinical trialsControlled Clinical Trials, 1986